Launch Plans Q4, 2024
The JV / Collaborative Partnership based BioPharma project is expected to be structured and incorporated in Q4, 2024 and subsequently Launch plans will be in Q1, 2025.
SPAC merger is expected to bring in approx $40M Investment to the merged entity.
$40 M
Investment availability for Drug Development, Early stage trials with AI Accelerated Methodologies
$5 M
Investment availability for Drug Development, Late Stage trials with AI-Accelerated Methodologies
$10 M
Global Expansion, Licensing deals and acquisitions
$15 M
Operating expenses post merger after SPAC advisory fees
$5 M